Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Neoplasm
83%
Malignant Neoplasm
71%
Gemcitabine
51%
Pharmacokinetics
50%
Clinical Trial
49%
Adverse Event
49%
Diseases
48%
Pancreas Adenocarcinoma
40%
Chemotherapy
37%
Pelareorep
35%
Progression Free Survival
32%
Tolerability
31%
Vorinostat
31%
Overall Survival
30%
Prostate Cancer
25%
Sorafenib
23%
Biological Marker
22%
Pancreas Cancer
22%
Pharmacodynamics
21%
Phase I Trials
21%
Metastatic Colorectal Cancer
20%
Drug Development
20%
Paclitaxel
20%
Phosphotransferase
20%
Colorectal Carcinoma
20%
Immunotherapy
19%
Anticancer Drug
18%
Hydroxychloroquine
18%
Pevonedistat
17%
Chronic Myeloid Leukemia
17%
Nivolumab
17%
Renal Cell Carcinoma
17%
Cisplatin
15%
Tumor Microenvironment
15%
Antitumor Activity
15%
Liver Cell Carcinoma
15%
Reoviridae
15%
Anemia
15%
Mammalian Target of Rapamycin Inhibitor
15%
Adenocarcinoma
14%
Mammalian Target of Rapamycin
14%
Placebo
14%
Phosphotransferase Inhibitor
14%
Oncolytic Virus
13%
Phase II Trials
13%
Vasculotropin
13%
Nilotinib
13%
Biliary Tract Cancer
13%
Clinical Study
13%
Keyphrases
Advanced Solid Tumors
77%
Phase II Study
45%
Solid Tumors
43%
Gemcitabine
38%
Phase I Study
38%
Apoptosis
37%
Tolerability
35%
In Cancer
35%
Pharmacokinetics
33%
Hepatocellular Carcinoma
32%
Overall Survival
32%
Vorinostat
31%
Tumor
29%
Partial Response
27%
Stable Disease
27%
Autophagy
26%
Cancer Patients
26%
Chemotherapy
26%
Adverse Events
25%
Metastatic Colorectal Cancer (mCRC)
25%
Phase I Clinical Trial
25%
Induced Apoptosis
25%
Sorafenib
24%
Randomized Phase II Trial
24%
Pelareorep
23%
Metastatic Pancreatic Ductal Adenocarcinoma
23%
Safety Profile
23%
Targeted Therapy
21%
Reolysin
21%
Prostate Cancer
21%
Phase II Trial
21%
Malignancy
21%
Median Overall Survival
20%
Cancer Therapy
20%
Antitumor Activity
20%
Dose-limiting Toxicity
20%
Circulating Tumor Cells
19%
Chronic Myeloid Leukemia
19%
Radioembolization
19%
Median Progression-free Survival
19%
Drug Development
19%
Pancreatic Cancer
19%
Pembrolizumab
19%
Hydroxychloroquine
18%
Phase I Trial
18%
Tumor Microenvironment
17%
Alpha-fetoprotein
17%
TRAIL Receptors
17%
Aurora Kinase Inhibitor
17%
First-in-class
17%
Medicine and Dentistry
Overall Survival
36%
Prostate Cancer
30%
Pancreas Adenocarcinoma
30%
Neoplasm
30%
Hepatocellular Carcinoma
29%
Radioembolization
24%
Cancer
23%
Diseases
22%
Metastatic Colorectal Cancer
20%
Targeted Therapy
20%
Pembrolizumab
18%
Pelareorep
17%
Intraarterial Drug Administration
17%
Common Hepatic Artery
17%
Arm
17%
Epidermal Growth Factor Receptor
17%
Clinical Trial
15%
Progression Free Survival
15%
Gemcitabine
15%
Nilotinib
14%
Chronic Myelogenous Leukemia
14%
Tyrosine-Kinase Inhibitor
13%
Cancer Therapy
12%
Sorafenib
12%
Cholangiocarcinoma
12%
Adverse Event
12%
Tumor Xenograft
12%
Solid Malignant Neoplasm
12%
Colorectal Carcinoma
11%
Glycon
11%
Vorinostat
11%
Castration Resistant Prostate Cancer
11%
Oncolytic Virus
11%
Circulating Tumor Cell
11%
Triple Negative Breast Cancer
11%
Alpha-Fetoprotein
11%
Scoring System
11%
Hydroxychloroquine
11%
Mesenchymal-Epithelial Transition
11%
Autophagy
11%
Non Small Cell Lung Cancer
11%
Nivolumab
11%
Ipilimumab
11%
Yttrium 90
10%
Immunotherapy
9%
Vasculotropin
9%
Carcinogenesis
9%
Cisplatin
9%
Tumor Immunity
9%
Imatinib
8%